-
Inmagene Biopharmaceuticals Secures Exclusive License for HutchMed’s Drug Candidates IMG-007 and IMG-004
•
HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that Sino-US biotech Inmagene Biopharmaceuticals has exercised its option to license two drug candidates discovered by HutchMed, IMG-007 and IMG-004, under the terms of a strategic partnership signed on January 11, 2021. Upon the exercise of these options and subject to…
-
Luye Pharma’s Paliperidone Palmitate NDA Avoids Patent Lawsuit, Clears Path for FDA Approval
•
Luye Pharma Group (HKG: 2186), a China-based pharmaceutical company, has announced that the New Drug Application (NDA) submitted to the US FDA via the 505(b)(2) route for its paliperidone palmitate extended-release injectable suspension (LY03010) has not faced a patent infringement lawsuit in the US. This follows the FDA’s acceptance of…
-
Matridx Bio Secures Series C+ Funding to Advance Infectious Pathogens Diagnostics
•
Hangzhou Matridx Biotechnology Co., Ltd, a specialist in molecular diagnostics for infectious pathogens based in China, has reportedly secured “hundreds of millions” of renminbi in a Series C+ financing round. The investment was led by a state-owned fund in Yuhang, Zhejiang province, and other undisclosed participants. The funds raised will…
-
China Medical System Reclaims Rights to Velphoro from WinHealth in Greater China
•
China Medical System Holdings Ltd (CMS, HKG: 0867) has announced a rights assignment agreement with fellow Chinese firm WinHealth Investment (HK) Ltd concerning Velphoro (sucroferric oxyhydroxide). Initially, CMS entered into a licensing agreement with WinHealth in June of the previous year, which granted WinHealth exclusive rights for regulatory filing, import,…
-
Sichuan’s Ancocare Gets FDA Green Light for Phase I/III Study of Oncolytic Virus in Neuroblastoma
•
Sichuan-based Flavivirus technology platform developer Ancocare has announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a Phase I/III clinical study for its double spear type I oncolytic virus DS1-H2-1 in neuroblastoma. The product, which leverages the Flavivirus technology platform, is a positive…
-
Siemens Healthineers Posts 5.7% Q1 2024 Sales Growth, Exceeds Pre-Pandemic Levels
•
Siemens Healthineers AG (ETR: SHL), based in Germany, has released its quarterly report for the first quarter of the fiscal year 2024, concluded on December 31, 2023. On a currency-adjusted basis, sales increased by 5.7% to EUR 5.18 billion (USD 5.6 billion). When excluding the impact of COVID-19-related sales, the…
-
Roche Posts Modest 2023 Growth Amid Shifts in Demand for COVID-Related Products
•
Swiss pharmaceutical giant Roche (SWX: ROG) has published its 2023 financial results, showing a modest 1% year-on-year (YOY) increase in global sales at constant exchange rates (CER) to CHF 58.7 billion (USD 68.5 billion). This growth was primarily due to a 6% YOY expansion in the pharmaceutical business to CHF…
-
Teva Pharmaceuticals Initiates Spin-off of TAPI Unit, Targeting 2025 for Completion
•
Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) a transnational generic drugs giant with Israeli and U.S. origins, has confirmed speculation in the market by announcing its intention to spin off its Active Pharmaceutical Ingredient (API) division, TAPI. This strategic move is part of Teva’s ‘pivot to growth’ initiative, aiming to streamline…
